NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

NOW APPROVED

Journey Medical Corporation Announces the U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg for Treatment of Papulopustular Rosacea.

Learn More

Company Overview

Journey Medical is focused on strategically identifying, acquiring, and successfully commercializing innovative and differentiated dermatology products. The Journey team is comprised of industry experts with decades of experience commercializing some of the most successful prescription dermatology brands. Our market knowledge and experience allow us to identify undervalued assets and future opportunities, then commercialize these opportunities through a best-in-dermatology marketing and sales organization.

Download Presentation View Management Team

Latest News

View all news

Latest Financial Results

View All SEC Filings

Q2 2025

Quarter Ended Jun 30, 2025

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2024

Report Links

Contacts

Corporate

Journey Medical Corporation
9237 East Via De Ventura
Suite 105
Scottsdale, AZ 85258
T: 480-434-6670
contact@jmcderm.com

Investor Relations

Jaclyn Jaffe
T: 781-652-4500
ir@jmcderm.com

Transfer Agent

VStock Transfer
Allison Niccolls
allison@vstocktransfer.com